Breast Cancer Treatment in Hyderabad

Reviewed May 2026  ·  Dr. Madhav Danthala

Breast cancer is the most commonly diagnosed cancer in Indian women, and the disease that benefits most from early, structured care. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted and hormonal therapy, and second opinions for breast cancer at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.

Dr. Madhav Danthala, medical oncologist — breast cancer treatment and oncology care in Hyderabad
ER+ / PR+
Hormone receptors present
First-line: hormonal therapy. Often slower-growing.
HER2+
HER2 over-expressed
First-line: anti-HER2 plus chemo. Targeted and effective.
TNBC
No receptors, no HER2
First-line: chemo plus immunotherapy. More aggressive subtype.

Breast cancer is three diseases, not one. Subtype shapes the first-line plan, not just stage.

When to See a Doctor

Most breast lumps are not cancer. The pattern that matters is when something is new, persistent, or changing. Four signs warrant evaluation.

Four warning signs for breast cancer A central watercolor circle representing the breast, with four annotated callouts pointing to a new lump, skin changes, nipple changes, and the external concept of family history. A new lump Persistent, firm, painless in breast or underarm. Skin changes Dimpling, redness, or peau d'orange texture. Nipple changes New inversion, discharge, or scaling around it. Family history Breast or ovarian cancer in a close relative under 50. Most signs are not cancer. Persistence is what warrants the visit.

Dr. Danthala's Approach

Breast cancer care is rarely one-size-fits-all. Three principles shape every consultation.

  1. Subtype-led planning

    Every plan begins with an honest understanding of the cancer's biology — receptor status, grade, Ki-67, and genomic risk where relevant — not stage alone.

  2. More than one path

    For early-stage disease, surgery-first and neoadjuvant-chemotherapy-first are both medically defensible in selected cases. The right path depends on the patient, not just the protocol.

  3. Clear, structured communication

    Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries — so decisions are made calmly, not under pressure.

Treatment Options

Breast cancer is treated with a combination of local control (surgery, radiation) and systemic therapy (hormonal, targeted, chemotherapy, immunotherapy). The mix is built around the subtype and stage. Below are the major modalities patients should expect to discuss in a treatment-planning consultation.

Surgery

Lumpectomy or mastectomy, with sentinel-node biopsy

Most early-stage breast cancers can be treated with breast-conserving surgery (lumpectomy) followed by radiation, with outcomes equivalent to mastectomy. Sentinel lymph node biopsy has largely replaced full axillary dissection for most patients. Reconstruction options — immediate or delayed, implant or autologous — are part of the same conversation.

Hormonal therapy

Tamoxifen, aromatase inhibitors — five to ten years

For ER+ disease (around 70% of cases), endocrine therapy is the cornerstone. Premenopausal women typically start on tamoxifen; postmenopausal women on aromatase inhibitors (letrozole, anastrozole, exemestane). Newer agents — abemaciclib, ribociclib — are added for high-risk early disease and for advanced disease, significantly improving outcomes.

Anti-HER2 targeted therapy

Trastuzumab, pertuzumab, T-DXd

For HER2+ disease, anti-HER2 antibodies have transformed prognosis. Standard adjuvant therapy combines trastuzumab and pertuzumab with chemotherapy, given for one year. Trastuzumab deruxtecan (T-DXd) and tucatinib have changed outcomes in advanced and HER2-low disease. CNS-active regimens are available for brain metastases.

Chemotherapy & immunotherapy

Anthracyclines, taxanes, pembrolizumab for TNBC

Triple-negative breast cancer (TNBC) is treated primarily with chemotherapy. The KEYNOTE-522 protocol — pembrolizumab combined with neoadjuvant chemotherapy — is now standard for early-stage TNBC and significantly improves pathological complete response. PARP inhibitors (olaparib) are an option for BRCA-mutated TNBC. Adjuvant pembrolizumab continues for one year post-surgery.

Radiation therapy

Adjuvant radiation after breast-conserving surgery

Adjuvant radiation is standard after lumpectomy and is also considered after mastectomy for high-risk disease (large tumours, positive nodes). Hypofractionated regimens (15-16 fractions) and partial-breast irradiation are now routine for selected patients, reducing total treatment time without compromising outcomes.

Treatment is always shaped by the individual — subtype, stage, age, fertility goals, comorbidities, and patient preference. The list above is the menu. The right plan is built with the patient in the room.

Frequently Asked Questions

At what age should I start breast cancer screening in India?

For average-risk women, mammographic screening typically begins at age 40 and continues every 1 to 2 years. If you have a family history of breast or ovarian cancer, especially before age 50, screening should start earlier — often a decade before the youngest affected relative's age at diagnosis. BRCA1 and BRCA2 mutations raise lifetime risk for both breast and ovarian cancer (and prostate cancer in men) — genetic counselling shapes surveillance for the whole family.

Does every breast lump mean cancer?

No. The majority of breast lumps are benign — most often fibroadenomas, cysts, or fibrocystic changes. However, any new, persistent, or changing lump should be evaluated by a doctor with a clinical breast exam and imaging, particularly in women over 35.

What does ER positive, HER2 negative breast cancer mean?

ER positive means the cancer cells have receptors for the hormone estrogen and grow in response to it. HER2 negative means the cancer does not over-express the HER2 protein. ER+/HER2- is the most common subtype (around 70% of cases) and typically responds well to hormonal therapy alongside surgery and, when needed, chemotherapy.

Should I get a second opinion before starting treatment?

Yes — a second opinion is recommended, especially for newly diagnosed patients, for unusual or aggressive subtypes, or when recommendations seem unclear. In oncology, more than one defensible treatment path often exists. A second opinion confirms the plan or surfaces alternatives.

What is triple negative breast cancer (TNBC)?

Triple negative breast cancer is a subtype where the cancer cells do not have estrogen receptors, progesterone receptors, or HER2 over-expression. It tends to be more aggressive and is treated primarily with chemotherapy, often combined with immunotherapy. Newer regimens have significantly improved outcomes.

About Dr. Madhav Danthala

Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.

Read full profile, training, and credentials →

Trusted guidelines & further reading

From our blog

All blog posts →

Related Specialties